Search results for "Cardiology"

showing 10 items of 6064 documents

Should we measure routinely the LDL peak particle size?

2004

Low density lipoproteins (LDL) do not show in humans a normal distribution and comprise two different main fractions: large, buoyant (phenotype pattern A) and small, dense (phenotype pattern B) particles, that differ not only in size and density but also in physicochemical composition, metabolic behaviour and atherogenicity. The prevalence of small, dense LDL changes with age (30-35% in adult men, 5-10% in men <20 years and in pre-menopausal women, 15-25% in postmenopausal women) and is genetically influenced, with a heritability ranging from 35% to 45%. Small, dense LDL correlate negatively with plasma HDL levels and positively with plasma triglyceride levels and are associated with the me…

medicine.medical_specialtySmall dense LDLAcute myocardial infarctionCoronary artery diseaseRisk FactorsDiabetes mellitusInternal medicineDiabetes MellitusmedicineHumansMyocardial infarctionParticle SizeRisk factorNational Cholesterol Education ProgramTriglyceridesMetabolic Syndromebusiness.industryVascular diseasePreventionmedicine.diseaseLipoproteins LDLCoronary heart diseasePhenotypeCardiovascular DiseasesAtherosclerosiCirculatory systemCardiologylipids (amino acids peptides and proteins)Metabolic syndromeLipoproteins HDLCardiology and Cardiovascular Medicinebusiness
researchProduct

Sodium-hydrogen exchange inhibition: novel strategy to prevent myocardial injury following ischemia and reperfusion.

1999

Activation of Na+/H+ exchange and subsequent calcium overload in cardiac myocytes appear to play an important role in myocardial tissue injury following ischemia and reperfusion. Results of several in vitro studies in isolated myocytes and heart preparations and in vivo studies in pigs and rats have suggested that inhibition of Na+/H+ exchange is an effective means to prevent lethal reperfusion injury, arrhythmia, and improve myocardial contractile dysfunction. In patients with acute myocardial infarction (MI), any preventive agent is administered immediately before or shortly after reperfusion, rather than before the occurrence of coronary occlusion. The direct interventional approach to t…

medicine.medical_specialtySodium-Hydrogen Exchangersmedicine.medical_treatmentPremedicationIschemiaMyocardial InfarctionMyocardial Reperfusion InjuryPilot ProjectsGuanidineschemistry.chemical_compoundInternal medicineAngioplastyLactate dehydrogenasemedicineAnimalsHumansMyocardial infarctionSulfonesAngioplasty Balloon CoronaryInfusions IntravenousCariporidebiologybusiness.industrymedicine.diseaseRatschemistryCoronary occlusionAnesthesiaCardiologybiology.proteinCreatine kinaseCardiology and Cardiovascular MedicinebusinessReperfusion injuryAnti-Arrhythmia AgentsThe American journal of cardiology
researchProduct

European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the second international consensus conference …

2008

This document summarizes the available evidence and provides recommendations on the use of home blood pressure monitoring in clinical practice and in research. It updates the previous recommendations on the same topic issued in year 2000. The main topics addressed include the methodology of home blood pressure monitoring, its diagnostic and therapeutic thresholds, its clinical applications in hypertension, with specific reference to special populations, and its applications in research. The final section deals with the problems related to the implementation of these recommendations in clinical practice. ispartof: Journal of Hypertension vol:26 issue:8 pages:1505-1530 ispartof: location:Neth…

medicine.medical_specialtySpecial populationsPhysiologybusiness.industryMEDLINEConsensus conferenceMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREBlood Pressure Monitoring Ambulatoryguidelinesarterial hypertension cardiovascular risk home blood pressure monitoringClinical PracticeEuropeHypertensionInternal MedicinemedicineHumansBlood pressure monitoringHypertension diagnosisDrug MonitoringCardiology and Cardiovascular MedicineIntensive care medicinebusinessAntihypertensive Agents
researchProduct

C0307 Baseline characteristics and management of patients with splanchnic vein thrombosis: Results of an international registry

2012

medicine.medical_specialtySplanchnic vein thrombosisbusiness.industryInternal medicineBaseline characteristicsmedicineCardiologyHematologybusinessSurgeryThrombosis Research
researchProduct

C0322 Factors associated with therapeutic strategies in patients with splanchnic vein thrombosis: Results of an international registry

2012

medicine.medical_specialtySplanchnic vein thrombosisbusiness.industryInternal medicineCardiologymedicineIn patientHematologybusinessThrombosis Research
researchProduct

Critical role of cardiac magnetic resonance in the diagnosis of left-dominant arrhythmogenic cardiomyopathy: A paradigmatic case in a recreational mi…

2021

medicine.medical_specialtySports cardiologyCardiac magnetic resonancebusiness.industryCardiomyopathyCase Reportmedicine.diseaseDefibrillatorInternal medicineDiagnosisCardiologyMedicineCardiology and Cardiovascular MedicinebusinessCardiac magnetic resonanceLEFT DOMINANTArrhythmiaHeartRhythm Case Reports
researchProduct

Special Article - Exercise-induced right ventricular injury or arrhythmogenic cardiomyopathy (ACM): The bright side and the dark side of the moon.

2020

There is still debate on the range of normal physiologic changes of the right ventricle or ventricular (RV) function in athletes. Genetic links to arrhythmogenic cardiomyopathy (ACM) are well-established. There is no current consensus on the importance of extensive exercise and exercise-induced injury to the RV. During the intensive exercise of endurance sports, the cardiac structures adapt to athletic load over time. Some athletes develop RV cardiomyopathy possibly caused by genetic predisposition, whilst others develop arrhythmias from the RV. Endurance sports lead to increased volume and pressure load in both ventricles and increased myocardial mass. The extent of volume increase and cha…

medicine.medical_specialtySports medicineVentricular Dysfunction RightCardiomyopathy030204 cardiovascular system & hematologyRisk AssessmentBoth ventriclesSudden cardiac death03 medical and health sciences0302 clinical medicineInternal medicinemedicineGenetic predispositionHumansGenetic Predisposition to Disease030212 general & internal medicineCardiomegaly Exercise-InducedPathologicalExerciseArrhythmogenic Right Ventricular DysplasiabiologyVentricular Remodelingbusiness.industryAthletesMyocardiummedicine.diseasebiology.organism_classificationAdaptation PhysiologicalFibrosismedicine.anatomical_structureDeath Sudden CardiacVentricleAthletesHeart Disease Risk FactorsCardiologyPhysical EnduranceVentricular Function RightCardiology and Cardiovascular MedicinebusinessProgress in cardiovascular diseases
researchProduct

Decision making and devices approach in a case of left main coronary artery thrombus.

2014

☆ This statement is to certify that all authors have seen being submitted, have contributed significantly to the w legitimacy of the data and its interpretation, and ag International Journal of Cardiology. We attest that the artic has not received prior publication and is not under elsewhere. We adhere to the statement of ethical pub (Shewan LG et al 2013 in press). ☆☆ On behalf of all co-authors, the corresponding author the submission. ⁎ Corresponding author at: Division of Cardiology II, D and Cardiovascular Diseases, University Hospital Paolo Gi 90127 Palermo, Italy. Tel.: +39 1 6554303; fax: +39 1 65 E-mail address: odisseos86@alice.it (V. Sucato).

medicine.medical_specialtyStatement (logic)business.industryGeneral surgeryInterpretation (philosophy)Left main coronary arteryIntravascular ultrasound; Left main coronary artery; Thrombusmedicine.diseaseUniversity hospitalSettore MED/11 - Malattie Dell'Apparato CardiovascolaremedicineIntravascular ultrasoundThrombusCardiology and Cardiovascular MedicinebusinessThrombus
researchProduct

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart diseas…

2013

AIMS: The first aim was to critically evaluate the extent to which familial hypercholesterolaemia (FH) is underdiagnosed and undertreated. The second aim was to provide guidance for screening and treatment of FH, in order to prevent coronary heart disease (CHD).METHODS AND RESULTS: Of the theoretical estimated prevalence of 1/500 for heterozygous FH, &lt;1% are diagnosed in most countries. Recently, direct screening in a Northern European general population diagnosed approximately 1/200 with heterozygous FH. All reported studies document failure to achieve recommended LDL cholesterol targets in a large proportion of individuals with FH, and up to 13-fold increased risk of CHD. Based on prev…

medicine.medical_specialtyStatinAtherosclerosis; Cardiovascular disease; Cholesterol; Coronary heart disease; Low-density lipoproteinSettore MED/09 - Medicina Internamedicine.drug_classPopulationCHILDRENFamilial hypercholesterolemiaBile acid bindingCOST-EFFECTIVENESS ANALYSIS030204 cardiovascular system & hematologyLDL-CHOLESTEROLDIAGNOSIS03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeInternal medicineDiabetes mellitusmedicineMANAGEMENT030212 general & internal medicineeducationHealth aging / healthy living Cardiovascular diseases [IGMD 5]Alirocumabeducation.field_of_studyCYTOKINE PATTERN CHANGEbusiness.industryLow-density lipoproteinmedicine.diseaseAtherosclerosisCardiovascular diseaseLomitapideDENSITY-LIPOPROTEIN APHERESIS3. Good healthASSOCIATION EXPERT PANELCoronary heart diseaseEndocrinologyCholesterolchemistryCARDIOVASCULAR-DISEASEAtherosclerosiCardiology and Cardiovascular MedicinebusinessSTATIN TREATMENTmedicine.drugEuropean Heart Journal
researchProduct

Statin intolerance: new data and further options for treatment

2021

Purpose of review Hypercholesterolemia is a major risk factor for cardiovascular diseases. Administration of statins represents the cornerstone of the prevention and treatment of cardiovascular disease, with demonstrated long-term safety and efficacy. This review aims to revisit statin intolerance mechanisms, as well as to discuss new data and therapeutic options. Recent findings Although statins are well tolerated, myopathy and other adverse effects are a challenging problem, being the main reason for poor adherence to treatment and failure in lowering cardiovascular risk. Statin intolerance is the subject of ongoing research, as these drugs are widely used. There are alternative options o…

medicine.medical_specialtyStatinDosemedicine.drug_classHypercholesterolemiaDisease030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeHumansMedicinecardiovascular diseases030212 general & internal medicineRisk factorIntensive care medicineAdverse effectbusiness.industryCholesterolAnticholesteremic Agentsangiopoietin-like 3 protein inhibitors bempedoic acid ezetimibe proprotein convertase subtilisin-kexin type 9 inhibitors statin intolerance Cholesterol LDL Ezetimibe Humans Proprotein Convertase 9 Anticholesteremic Agents Cardiovascular Diseases Hydroxymethylglutaryl-CoA Reductase Inhibitors Hypercholesterolemianutritional and metabolic diseasesCholesterol LDLEzetimibeRegimenchemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsProprotein Convertase 9Cardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct